Keystone Lab Announces Addition of Xylazine Testing to its In-House Menu
10 Jul 2023
ASHEVILLE, N.C., July 10, 2023 /PRNewswire/ -- Keystone Lab, a dual-CAP accredited and CLIA certified lab based in Asheville, NC, has officially added xylazine to its in-house urine clinical toxicology menu. Keystone provides clinical and forensic toxicology testing services throughout the southeastern U.S. and is one of few labs in the nation to offer xylazine testing.
According to the U.S. Food and Drug Administration, xylazine is a non-opioid tranquilizer that is only authorized in the U.S. for veterinary use. Products containing xylazine most commonly use the street names of "tranq", "tranq dope", and "zombie drug".
The current presidential administration designated fentanyl combined with xylazine as an emerging threat to the United States. The DEA Laboratory System reported that in 2022, approximately 23% of fentanyl powder and 7% of fentanyl pills seized by the DEA contained xylazine. They also reported that xylazine-positive overdose deaths increased by 1,127% in the southern U.S. between 2020 and 2021, with those numbers continuing to increase.
"Xylazine is frequently used as an adulterant in heroin and illicit fentanyl, and its prevalence in toxicology samples are primarily from medico-legal death investigations and DUI cases. It has become a major issue in the U.S., with xylazine-positive overdose deaths dramatically increasing in southern states. Xylazine also has an extremely high presence in North Carolina counties, which has urged Keystone to move quickly toward test development for this drug," said Dr. James Bourland, Scientific Director of Keystone Lab. "Adding this test in-house will allow Keystone to better service the patients of our clients and provide additional peace of mind as xylazine usage continues to spread."
If testing for xylazine is a priority for your business, please contact Keystone Lab at 800-230-2991, or contact us directly on our website.
Resources:
https://www.dea.gov/sites/default/files/2022-12/The%20Growing%20Threat%20of%20Xylazine%20and%20its%20Mixture%20with%20Illicit%20Drugs.pdf
http://www.ncbop.org/PDF/XylazineExposureGuidanceMay162023.pdf
Kacinko, S., Mohr, A., Logan, B., Barbien, E. (2022) Xylazine: Pharmacology Review and Prevalence and Drug Combinations in Forensic Toxicology Casework. Journal of Analytical Toxicology,
46, 911-917
About Keystone Lab:
Keystone Lab is a dual CAP-accredited and CLIA certified lab providing clinical and forensic toxicology testing services for more than 35 years. Keystone has developed an innovative platform of services to ensure the success and growth of organizations throughout the United States. For more information about Keystone Lab, visit our Instagram, LinkedIn, Twitter, and Facebook pages.
Media Contact
David Price
Sales & Marketing Manager
[email protected]
828-771-3107
SOURCE Keystone Lab
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
-Targets
-Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.